Cerenome Inc. tripled its footprint at Levit Green, the 53-acre life sciences district adjacent to the Texas Medical Center.

The Houston-based central nervous system oncology company formerly known as Plus Therapeutics first leased 11,370 SF in December, and it has now expanded its lease to 36,500 SF, the Houston Business Journal reported. 

“Cerenome’s expansion is exactly the type of growth Levit Green was designed to support,” said John Mooz, senior managing director at Hines, the developer of Levit Green. 

“The company was able to move quickly into turnkey lab space and can now expand into a purpose-built environment on the same campus — demonstrating the flexibility we believe is increasingly important as life sciences companies grow,” Mooz said in a statement.

Levit Green’s first phase is a 290K SF, five-story laboratory and biomanufacturing facility that was completed in 2023. Hines said that building is part of a master plan that will offer a mix of research and production facilities, office, retail, residential and outdoor amenities.

Cerenome, with Hines, is designing and constructing a laboratory and office on the fifth floor of Phase 1. That is expected to be completed in the fourth quarter of 2027. 

This is one of the largest leases in Houston’s life sciences sector in recent years, Hines said in a press release. That market has also seen major wins in the past year, with pharmaceutical giants Eli Lilly and Bristol Myers Squibb both committing to multibillion-dollar manufacturing investments in Northeast Houston’s Generation Park.